Dx & Vx Co., Ltd.

Emerging as a next-generation vaccine amidst global resurgence of COVID-19 Expanding v arious pipelines other than universal COVID vaccine SEOUL, South Korea, May 29, 2025 /PRNewswire/ -- Bio-healthcare company Dx&Vx (DXVX) has officially announced the acceleration of its development program for a universal COVID-19 vaccine, following the recent acquisition of related technology. Designed to provide immunity against both current and future variants of the coronavirus, this next-generation vaccine is drawing global attention amid a new wave of COVID-19 cases worldwide. Global health organizations, including the WHO, have raised concerns about rising COVID-19 cases in parts of Europe, Asia, and North America. These warnings have highlighted the urgent need for more robust and lasting immune solutions against evolving virus variants. DXVX, a company led by COREE Group Chairman Chong-Yoon Lim, the eldest son of Hanmi Pharmaceutical Group's founder, secured the universal vaccine technology late last year. The vaccine under development uses a virus-like particle (VLP) platform, which offers greater stability and ease of storage compared to mRNA vaccines. Theoretically, it has the potential to prevent infections caused by all known and future COVID-19 variants. Currently, DXVX is advancing through the regulatory procedures necessary to initiate Phase 2 clinical trials in South Korea, the U.S., and Southeast Asia. After successfully completing Phase 1 trials in the U.S. and South Africa, the company is preparing its Investigational New Drug (IND) applications for global Phase 2 studies. DXVX also acquired a universal COVID-19 treatment technology last year from LUCA AI Cell. DXVX stated, "Luca's treatment technology has efficacy test data for dozens of lethal viruses, including COVID-19," and added, "It is expected to enable the development of a new-concept COVID-19 treatment.". In addition to its universal COVID-19 vaccine and treatment, Dx&Vx (DXVX) is actively targeting the global pharmaceutical and biotech market through a diverse pipeline, including: A next-generation mRNA vaccine platform capable of ultra-long-term storage at room temperature An oral obesity treatment The OVM-200 cancer vaccine based on the ROP platform technology. In particular, the mRNA vaccine platform capable of ultra-long-term storage at room temperature is considered a game-changer, as it enables vaccination even in countries with limited cold-chain infrastructure, thereby lowering geographical barriers in responding to infectious diseases. Discussions to sign Material Transfer Agreements (MTAs) with major domestic and global mega pharmaceutical companies have recently accelerated, indicating that the platform has entered the late stages of licensing out, with visible outcomes expected within this year. In addition, the oral obesity treatment, which is about to enter clinical trials, addresses the inconvenience of injection-based therapies while demonstrating effectiveness in improving fat metabolism, with related patents already filed. The OVM cancer vaccine represents a novel immuno-oncology approach targeting solid tumors and is also open to potential joint development with global pharmaceutical companies. A DXVX spokesperson stated, "We are committed to advancing the development of the universal COVID-19 vaccine, while also preparing for potential future COVID-19 variants and lethal infectious diseases, such as 'Disease X'." The spokesperson added, "In addition to the major pipelines currently being promoted for licensing out, we are actively investing in R&D across multiple technology assets and expect sustainable long-term outcomes." SOURCE Dx&Vx WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Novo Nordisk's dealmaking dispute with KBP Biosciences, AstraZeneca's purchase of FibroGen China and Ono's FDA approval for a rare tumor drug made our news this week. Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing deal worth up to $1.3 billion. AstraZeneca is buying out its roxadustat partner FibroGen in China. Ono Pharmaceutical's $2.4 billion Deciphera acquisition has borne fruit. And more.1. Novo Nordisk to sue KBP Biosciences over alleged fraudulent claims on kidney disease drugNovo Nordisk is alleging that KBP Biosciences intentionally withheld negative clinical data before the Danish company bought the latter’s hypertension candidate ocedurenone in a potential $1.3 billion deal in 2023. Novo plans to seek $830 million in damages from the Singaporean biotech, which was founded by Huang Zhenhua in China. The Singapore International Commercial Court has ordered a freeze of the assets of KBP and Huang as Novo prepares to launch arbitration proceedings in New York.2. AstraZeneca pays $160M for FibroGen's China unit, regional rights to roxadustatAfter ditching FibroGen’s chronic kidney disease drug roxadustat in the U.S., AstraZeneca has decided to take full control of the HIF-PH inhibitor in China. The British pharma is paying $160 million to buy FibroGen’s China unit. Last year, AZ recorded $336 million in revenue from the drug, sold as Evrenzo in China, a 22% increase despite generic competition.3. FDA approves Ono's rare tumor drug from $2.4B Deciphera buyoutOno Pharmaceutical’s Deciphera Pharmaceuticals has won FDA approval for Romvimza as a competitor to Daiichi Sankyo’s Turalio in symptomatic tenosynovial giant cell tumor. The Japanese pharma bought the U.S. biotech last year for $2.4 billion to expand its targeted oncology portfolio and boost its U.S. footprint. Compared with Turalio, Romvimza holds a convenience edge and does not come with a black box warning.4. Otsuka breaks up with cancer candidates on strategic groundsOtsuka has nixed several clinical cancer programs for “strategic reasons.” Among the candidates, the only one that the company was developing in the U.S. was OPB-111077, an oral STAT inhibitor that entered the clinic in 2012. The drug was mostly recently tested in a lymphoma trial starting in 2019 until enrollment stopped last year. The other three are being tested only in Japan.5. Siemens Healthineers plans 'mega depots' to bolster US supply chain amid 'geopolitical uncertainties'As President Donald Trump’s new tariffs on China and Mexico are expected to impact medical devices, Siemens Healthineers said it’s building new “mega depots” for spare parts and other inventory in New York City and Oakland, California. The company cited “geopolitical uncertainties” as a potential threat to a stable medtech supply chain.6. Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunnerRadiance Biopharma is paying $15 million upfront for rights to a ROR1-directed antibody-drug conjugate from a subsidiary of China’s CSPC Pharmaceutical. The deal could be worth more than $1 billion if the drug reaches certain sales milestones. After reporting a 100% complete response rate, Merck & Co. has moved its ROR1 ADC into phase 3 testing in diffuse large B-cell lymphoma.Other News of Note: 7. Amid Merck supply squeeze, ImmunityBio and Serum Institute snag FDA blessing for BCG expanded access program8. Ascletis' swift surge into obesity continues with competitive oral GLP-1 data9. FDA hits pair of Indian API makers with warning letters, import alerts

- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine - Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications SEOUL, South Korea, Jan. 13, 2025 /PRNewswire/ -- Since the COVID-19 pandemic, mRNA vaccines have been recognized as the most important platform for infectious disease prevention and continue to be utilized across various fields. However, concerns remain about the limitations of the technology, including the need for ultra-cold storage and side effects associated with lipid nanoparticles (LNP) required for mRNA delivery. Recently, new platforms are emerging as alternatives to mRNA vaccines. Continue Reading VLP vaccine image Ferritin-based vaccine can simultaneously activate both humoral and cellular immunity, whereas traditional vaccines primarily depend on humoral immunity (Global Journal ‘Vaccines’, December 2024) One such platform is the Virus-Like Particle (VLP) vaccine technology. While not as widely known as mRNA vaccines, Ferritin based nano platform VLP vaccines have been noted for their potential to significantly enhance immune responses due to their structural stability. VLPs mimic the structural characteristics of target viruses, presenting antigens in a virus-like configuration. Particularly, the Ferritin based nano platform VLP vaccine is being evaluated as a powerful platform capable of accommodating multiple virus antigens simultaneously, making it suitable for addressing various mutations. DXVX(180400) has recently acquired global development rights from Stanford University for an innovative universal coronavirus vaccine based on the Ferritin based nano platform VLP technology. Through the dedication and persuasive efforts of Chong-Yoon Lim, Chairman of the COREE Group and major shareholder of DXVX, this collaboration was established. Ferritin, a protein that stores iron, can self-assemble into hollow spherical nanoparticles depending on pH conditions. Dx&Vx's VLP vaccine utilizes this ferritin-based nanoparticle platform to display the spike protein of the coronavirus on its surface, making a universal coronavirus vaccine. The Ferritin-based VLP vaccine structurally mimics the size and shape of the COVID-19 virus, enabling the immune system to recognize it as the actual virus. This VLP vaccine can induce a strong cytotoxic T-cell response, effectively combating viral infections. The human immune system defends against viral infections through both humoral and cellular immune responses, a process known as 'cross-presentation.' Vaccines that stimulate both immune systems simultaneously provide more robust and long-lasting immunity compared to vaccines that only induce antibody production. Cytotoxic T cells, which play a critical role in destroying virus-infected or cancerous cells, do not directly recognize antigens. Instead, T cells only identify antigen fragments presented by major histocompatibility complex (MHC) molecules, thereby targeting and eliminating infected cells. Notably, Dx&Vx's vaccine is designed to strongly induce both humoral and cellular immune responses, making it superior to traditional antigen protein-based vaccines that primarily focus on humoral immunity. The Ferritin-based VLP vaccine, now preparing for global Phase 2 clinical trials, is expected to demonstrate superior immune induction effects compared to marketed vaccines. According to animal studies conducted by the Walter Reed Army Institute of Research (WRAIR), the Ferritin-based VLP vaccine demonstrated neutralizing antibody levels more than ten times higher than those of mRNA vaccines. Additionally, the Wuhan Institute of Virology in China reported that the Ferritin-based VLP vaccine outperformed mRNA vaccines. Collectively, these findings indicate that the Ferritin-based VLP vaccine may offer superior protective effects compared to traditional vaccine platforms. Moreover, this vaccine has demonstrated stability at room temperature for up to two weeks and has shown the ability to induce strong immune responses even in previously unexposed organisms. These characteristics distinguish it from mRNA-based vaccines. The platform has also been validated for its applicability in polyvalent vaccines for broad mutation coverage, offering versatility in administration routes and various other advantages. Dx&Vx's VLP universal coronavirus vaccine has already completed Phase 1 clinical trials in the United States and South Africa, where it was evaluated against mRNA vaccines for antibody titers and adverse effects. The results have confirmed the technological superiority of this vaccine platform. The Ferritin platform-based VLP vaccine is expected to be extended for the development of vaccines against various lethal viruses, such as influenza and Ebola, playing a critical role in future pandemic responses. A Dx&Vx representative stated, "The ultimate goal of the Ferritin platform-based VLP vaccine under development is to provide a safe, superior, and convenient vaccine that offers maximum protection against various deadly infectious diseases for humanity." SOURCE Dx&Vx WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED